API
< Back to all clusters
[HEALTH] · United Kingdom, Sweden, Denmark · 2 sources

started · updated

New medical research explores potential benefits of baxdrostat and obesity drugs

Recent scientific studies have highlighted potential breakthroughs in treating hypertension and protecting cognitive functions.

A study led by Professor Maurice Brown at Queen Mary University of London suggests that the drug baxdrostat may significantly reduce blood pressure in patients with primary aldosteronism. In clinical observations, patients who took the medication daily for six to twelve months showed improved blood pressure levels that persisted for up to two years after discontinuing the treatment. Notably, nearly one-quarter of the patients were able to maintain normal blood pressure without further medication.

Separately, research published in the journal Science by investigators from the University of Gothenburg and the University of Copenhagen examines the impact of obesity medications, specifically semaglutide and tirzepatide, on brain health. While these drugs are primarily used for weight loss and type 2 diabetes management, data suggests they may influence biological mechanisms related to memory, learning, and attention. However, researchers caution that current evidence is insufficient to confirm if these drugs can prevent dementia or slow neurodegenerative diseases.

Entities

Maurice Brown · Queen Mary University of London · Science · University of Copenhagen · University of Gothenburg